Peringatan Keamanan

There is no information on the LD50 of darvadstrocel. No case of overdose has been reported.L39759

Darvadstrocel

DB16581

biotech approved experimental

Deskripsi

Darvadstrocel is a suspension of expanded human allogeneic adipose-derived mesenchymal stem cells extracted from the subdermal adipose tissue of healthy donors via liposuction.A244524 Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel. It is indicated for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s disease when fistulas have shown an inadequate response to at least one conventional or biologic therapy.L39759 It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication. Perianal fistula is a common manifestation of Crohn’s disease and is often difficult to manage, as it may be associated with complex presentations and symptoms. Darvadstrocel exhibits immunomodulatory and anti-inflammatory effects: it aims to reduce local inflammation and enhance tissue repair in perianal fistulas.A244524

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Pharmacokinetic information is not applicable.
Volume Distribusi In preclinical trials where human expanded adipose stem cells were administered via perianal and intrarectal injection in athymic rats, cells were detectable in the rectum and jejunum at the site of injection for at least 14 days and were undetectable after 3 months.[L39759]
Klirens (Clearance) Pharmacokinetic information is not applicable.

Absorpsi

Pharmacokinetic information is not applicable.

Metabolisme

Pharmacokinetic information is not applicable.

Rute Eliminasi

Pharmacokinetic information is not applicable.

Interaksi Obat

0 Data
Tidak ada data.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 30298387
    Scott LJ: Darvadstrocel: A Review in Treatment-Refractory Complex Perianal Fistulas in Crohn's Disease. BioDrugs. 2018 Dec;32(6):627-634. doi: 10.1007/s40259-018-0311-4.
  • PMID: 32354239
    Meng ZW, Baumgart DC: Darvadstrocel for the treatment of perianal fistulas in Crohn's disease. Expert Rev Gastroenterol Hepatol. 2020 Jun;14(6):405-410. doi: 10.1080/17474124.2020.1764349. Epub 2020 May 20.
  • PMID: 18626977
    Bataille F, Rohrmeier C, Bates R, Weber A, Rieder F, Brenmoehl J, Strauch U, Farkas S, Furst A, Hofstadter F, Scholmerich J, Herfarth H, Rogler G: Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflamm Bowel Dis. 2008 Nov;14(11):1514-27. doi: 10.1002/ibd.20590.
  • PMID: 19487818
    Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 2009 Jun;119(6):1420-8. doi: 10.1172/JCI39104.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Alofisel
    Injection, suspension • 5000000 cells/ml • Intralesional • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul